Key Highlights
- On April 7, 2026, Hologic transitioned to private ownership under Blackstone and TPG in a transaction valued at up to $79 per share.
- Shareholders obtained $76 cash per share alongside a contingent value right potentially worth an additional $3, dependent on Breast Health division performance.
- Abu Dhabi Investment Authority and GIC participated as minority stakeholders.
- After more than a dozen years leading the company, Stephen MacMillan stepped down as CEO, with Joe Almeida taking the reins.
- Trading in HOLX shares has ended, with delisting from Nasdaq now complete.
The women’s health diagnostics company Hologic closed its transition to private ownership on April 7, 2026, as private equity firms Blackstone and TPG finalized their acquisition at a valuation reaching $79 per share.
Initially unveiled on October 21, 2025, the acquisition secured shareholder backing on February 5, 2026. The deal structure also incorporated minority stakes from an Abu Dhabi Investment Authority subsidiary and a GIC affiliate.
Investors received an upfront cash payment of $76 for each share held. Additionally, they were granted a contingent value right—non-transferable—potentially worth an extra $3 per share. This CVR distributes in two phases of up to $1.50 each, contingent upon Hologic achieving specific worldwide revenue benchmarks for its Breast Health segment during fiscal 2026 and 2027.
The contingent payment mechanism means shareholders only realize the complete $79 valuation if the company meets predetermined revenue objectives. This performance-linked component adds an interesting dimension to the transaction’s ultimate worth.
Prior to the deal’s completion, Hologic generated $4.13 billion in trailing twelve-month revenue, maintained a 60% gross margin, and showed a current ratio exceeding 4. The company’s market capitalization stood at $16.97 billion.
Its latest quarterly performance disappointed market watchers. The company posted $1.05 billion in revenue against analyst expectations of $1.07 billion, while adjusted earnings per share of $1.04 underperformed the $1.09 consensus estimate.
Executive Transition
Stephen MacMillan concluded his tenure as CEO upon deal closure, wrapping up more than twelve years of leadership. Joe Almeida assumed the Chief Executive Officer position effective at closing and simultaneously became the company’s only board member.
Almeida brings extensive medical technology experience. His previous role as Chairman, President and CEO of Baxter International spanned from 2016 through early 2025. Earlier in his career, he held equivalent positions at Covidien before Medtronic’s 2015 acquisition of that company.
The executive appointment reflects the new ownership’s strategic vision—Blackstone, overseeing $1.3 trillion in assets under management, and TPG, managing $303 billion—prioritizing expansion under private ownership.
The transaction also restructured Hologic’s equity compensation framework. Stock option holders and those with equity awards received settlement through cash payments combined with CVR-linked distributions, while deeply out-of-the-money options were terminated without compensation.
Public Market Exit
HOLX shares have permanently stopped trading. The company’s delisting from Nasdaq is now official, transforming it into a fully owned entity within the Blackstone-TPG investment vehicle.
Shares finished their final trading session at $76.01—virtually matching the 52-week peak of $76.07, demonstrating how accurately the market anticipated the deal’s successful conclusion.
Ahead of the closing, six Wall Street analysts lowered their earnings projections for future reporting periods. The final published analyst recommendation carried a Buy rating alongside an $83 price objective.
Before the transaction’s completion, InvestingPro had awarded Hologic a “GREAT” rating for overall financial strength.
